HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Facial Hypertrichosis

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Skin and Connective Tissue Diseases
- Skin Diseases: 13127
  - Hair Diseases: 36
    - Hypertrichosis: 520
      - Facial Hypertrichosis: 10

Related Diseases

1.	Hyperpigmentation
2.	Porphyria Cutanea Tarda
3.	Hypothyroidism
4.	Dizziness (Lightheadedness)

Experts

1.	Alevizopoulos, Nektarios: 1 article (07/2022)
2.	Alexandris, Dimitrios: 1 article (07/2022)
3.	Gakiopoulou, Charikleia: 1 article (07/2022)
4.	Palamaris, Kostas: 1 article (07/2022)
5.	Theocharis, Stamatios: 1 article (07/2022)
6.	Perera, Eshini: 1 article (01/2017)
7.	Sinclair, Rodney: 1 article (01/2017)
8.	Ben Hamida, Myriam: 1 article (08/2013)
9.	Benmously Mlika, Rym: 1 article (08/2013)
10.	Dorbani Ben Thabet, Imen: 1 article (08/2013)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Facial Hypertrichosis:

1.	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/01/2009 - "A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva)." 08/01/2010 - "Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib."
2.	Cetuximab (Erbitux)FDA Link 04/01/2023 - "Pinnae and facial hypertrichosis induced by cetuximab." 12/01/2006 - "Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody."
3.	ErbB Receptors (EGF Receptor)IBA 08/01/2010 - "Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib."
4.	PorphyrinsIBA 10/01/1988 - "Porphyria cutanea tarda, a metabolic disorder of heme biosynthesis, is characterized by cutaneous hyperpigmentation, facial hypertrichosis, dark urine, and a distinctive pattern of excess porphyrin production. "
5.	Minoxidil (Rogaine)FDA LinkGeneric 08/01/2013 - "Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy."
6.	Heme (Haem)IBA 10/01/1988 - "Porphyria cutanea tarda, a metabolic disorder of heme biosynthesis, is characterized by cutaneous hyperpigmentation, facial hypertrichosis, dark urine, and a distinctive pattern of excess porphyrin production. "
7.	Estrone FDA Link 07/01/1947 - "Estrone and alpha-estradiol, applied locally, ineffective in reducing facial hypertrichosis."
8.	Estradiol (Delestrogen)FDA LinkGeneric 07/01/1947 - "Estrone and alpha-estradiol, applied locally, ineffective in reducing facial hypertrichosis."
9.	Monoclonal AntibodiesIBA 12/01/2006 - "Facial hypertrichosis induced by Cetuximab, an anti-EGFR monoclonal antibody."
10.	Transaminases (Aminotransferases)IBA 05/01/1983 - "Slight hyperpigmentation, facial hypertrichosis, and hypothyroidism were seen in affected individuals who also had prolonged increase in serum transaminase, gamma-glutamyltranspeptidase, and alkaline phosphatase activities. "

Therapies and Procedures

1.	Solid-State Lasers 08/01/2013 - "Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy."
2.	Therapeutics 08/01/2013 - "Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy."
3.	Radiotherapy 06/01/1960 - "[Radiotherapy of facial hypertrichosis]."
4.	Lasers (Laser) 01/01/2017 - "Five women who described trichodynia at baseline, noted improvement or resolution within 3 months. Mean change in blood pressure was minus 0.5 mmHg systolic and plus 2.1 mmHg diastolic. Two patients developed transient postural dizziness that resolved with continued treatment. One patient developed ankle oedema. Thirteen women developed facial hypertrichosis. For 6 patients this was mild and did not require treatment; 4 had waxing of their upper lip or forehead; 3 had laser hair removal. No patients developed any haematological abnormality. All 36 women completed 12 months of treatment. "
5.	Hair Removal (Depilation) 01/01/2017 - "Five women who described trichodynia at baseline, noted improvement or resolution within 3 months. Mean change in blood pressure was minus 0.5 mmHg systolic and plus 2.1 mmHg diastolic. Two patients developed transient postural dizziness that resolved with continued treatment. One patient developed ankle oedema. Thirteen women developed facial hypertrichosis. For 6 patients this was mild and did not require treatment; 4 had waxing of their upper lip or forehead; 3 had laser hair removal. No patients developed any haematological abnormality. All 36 women completed 12 months of treatment. "